Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol sees Medarex acquisition as a way to expand its immunology and oncology pipeline in preparing for Plavix generics in 2012.

You may also be interested in...



Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono

In a transaction that involves no cash moving in either direction, Bristol-Myers Squibb has expanded its territorial rights to an oncology antibody acquired in its 2009 purchase of Medarex, while Ono Pharmaceutical gets co-development and co-commercialization rights to rheumatoid arthritis drug Orencia (abatacept) in Japan

Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono

Rather than financial considerations, Ono Pharmaceutical will receive co-development and co-commercialization rights to rheumatoid arthritis drug Orencia in Japan.

Don't Call It An Asset Swap: Bristol Expands Rights To Anti-PD-1 Antibody In No-Cash Transaction With Ono

Rather than financial considerations, Ono Pharmaceutical will receive co-development and co-commercialization rights to rheumatoid arthritis drug Orencia in Japan.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS069734

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel